Who is sponsoring NCT03072966?

NCT03072966 is sponsored by Asan Medical Center.

What drugs are being tested in NCT03072966?

Interventions in NCT03072966: Wearable device (Fitbit Charge HR® or Fitbit Alta ®).

What condition does NCT03072966 study?

NCT03072966 studies Breast Cancer, Quality of Life.

Is NCT03072966 still recruiting?

NCT03072966 is currently completed. Last updated 10 January 2019.

Last reviewed 2019-01-10 · How we verify

NCT03072966

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Development of Distress Management Algorithms Using Mobile Device Based Health Logs in Breast Cancer Survivors

Completed NA Last updated 10 January 2019

What this trial tests

NA trial testing Wearable device (Fitbit Charge HR® or Fitbit Alta ®) in Breast Cancer in 160 participants. Completed in 31 December 2018.

Timeline

13 June 2017

Primary endpoint
31 October 2018

31 December 2018

Quick facts

Lead sponsor	Asan Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	160
Start date	13 June 2017
Primary completion	31 October 2018
Estimated completion	31 December 2018
Sites	1 location across South Korea

Drugs / interventions tested

Wearable device (Fitbit Charge HR® or Fitbit Alta ®)

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Quality of Life — all drugs for Quality of Life →

Sponsor

Asan Medical Center

Who can join

Adults 20 to 60, female only, with Breast Cancer or Quality of Life. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Distress monitoring is an important issue in cancer survivors. However, conventional distress screening is very difficult to perform. This study investigates the efficacy of wearable device as a tool of distress monitoring in breast cancer survivors.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

An Assessment of Physical Activity Data Collected via a Smartphone App and a Smart Band in Breast Cancer Survivors: Observational Study.
Chung IY, Jung M, Lee SB, Lee JW, et al · · 2019 · cited 28× · PMID 31493319 · DOI 10.2196/13463
Exercise Promotion and Distress Reduction Using a Mobile App-Based Community in Breast Cancer Survivors.
Chung IY, Jung M, Park YR, Cho D, et al · · 2019 · cited 23× · PMID 31998651 · DOI 10.3389/fonc.2019.01505
Integrating Artificial Intelligence-Driven Wearable Technology in Oncology Decision-Making: A Narrative Review.
Birla M, Rajan, Roy PG, Gupta I, et al · · 2025 · cited 14× · PMID 39072365 · DOI 10.1159/000540494
A Mobile Technology for Collecting Patient-Reported Physical Activity and Distress Outcomes: Cross-Sectional Cohort Study.
Jung M, Lee S, Kim J, Kim H, et al · · 2020 · cited 6× · PMID 32364508 · DOI 10.2196/17320

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Asan Medical Center trials

Trials by the same sponsor.

NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03072966 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
Last refreshed: 10 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03072966.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing